Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY


3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Lipids
3.2.1. Types of Lipids
3.3. Applications of Lipids in Pharmaceutical Industry
3.4. Challenges Associated with Lipid Manufacturing
3.5. Need for Outsourcing Lipid Manufacturing
3.6. Concluding Remarks

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Lipid Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Lipid Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Service(s) Offered
4.2.8. Analysis by Types of Lipids Manufactured
4.2.8.1. Analysis by Types of Lipids Manufactured and Company Size
4.2.8.2. Analysis by Types of Lipids Manufactured and Scale of Operation
4.2.8.3. Analysis by Types of Lipids Manufactured and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4 Lipid Contract Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Lipid Contract Manufacturers in North America
5.4.2. Company Competitiveness Analysis: Lipid Contract Manufacturers in Europe
5.4.3. Company Competitiveness Analysis: Lipid Contract Manufacturers in Asia-Pacific

6. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Avanti Polar Lipids
6.2.1. Company Overview
6.2.2. Lipid Manufacturing Service Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook
6.3. Creative Biolabs
6.3.1. Company Overview
6.3.2. Lipid Manufacturing Service Offerings
6.3.3. Manufacturing Facilities
6.3.4. Recent Developments and Future Outlook
6.4. Exelead
6.4.1. Company Overview
6.4.2. Lipid Manufacturing Service Offerings
6.4.3. Manufacturing Facilities
6.4.4. Recent Developments and Future Outlook
6.5. FormuMax Scientific
6.5.1. Company Overview
6.5.2. Lipid Manufacturing Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook
6.6. T&T Scientific
6.6.1. Company Overview
6.6.2. Lipid Manufacturing Service Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Lipid Manufacturing Service Offerings
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook
7.3. CordenPharma
7.3.1. Company Overview
7.3.2. Lipid Manufacturing Service Offerings
7.3.3. Manufacturing Facilities
7.3.4. Recent Developments and Future Outlook
7.4. Evonik
7.4.1. Company Overview
7.4.2. Lipid Manufacturing Service Offerings
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook
7.5. Fresenius Kabi
7.5.1. Company Overview
7.5.2. Lipid Manufacturing Service Offerings
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook
7.6. Merck KGaA
7.6.1. Company Overview
7.6.2. Lipid Manufacturing Service Offerings
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Fujifilm
8.2.1. Company Overview
8.2.2. Lipid Manufacturing Service Offerings
8.2.3. Manufacturing Facilities
8.2.4. Recent Developments and Future Outlook
8.3. Nagase Medicals
8.3.1. Company Overview
8.3.2. Lipid Manufacturing Service Offerings
8.3.3. Manufacturing Facilities
8.3.4. Recent Developments and Future Outlook
8.4. Nippon Fine Chemical
8.4.1. Company Overview
8.4.2. Lipid Manufacturing Service Offerings
8.4.3. Manufacturing Facilities
8.4.4. Recent Developments and Future Outlook
8.5. TTY Biopharm
8.5.1. Company Overview
8.5.2. Lipid Manufacturing Service Offerings
8.5.3. Manufacturing Facilities
8.5.4. Recent Developments and Future Outlook
8.6. VCARE Bio Labs
8.6.1. Company Overview
8.6.2. Lipid Manufacturing Service Offerings
8.6.3. Manufacturing Facilities
8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Lipid Contract Manufacturing Market: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Product
9.3.4. Analysis by Type of Focus Area
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Geographical Analysis
9.3.6.1. Region-wise Distribution
9.3.6.2. Country-wise Distribution

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Lipid Contract Manufacturing Market: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Expansion and Scale of Operation
10.2.4. Analysis by Type of Product
10.2.5. Analysis by Amount Invested
10.2.6. Analysis by Company Size and Location of Headquarters
10.2.7. Analysis by Location of Expanded Facility
10.2.8. Most Active Players: Analysis by Number of Recent Expansions
10.2.9. Geographical Analysis
10.2.9.1. Region-wise Distribution
10.2.9.2. Country-wise Distribution

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Lipid Contract Manufacturing: Installed Global Capacity (Million Liters)
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1. Chapter Overview
12.2. Assumptions and Parameter Definitions
12.3. Lipid Contract Manufacturing: Make Versus Buy Decision Making
12.3.1. Scenario 1
12.3.2. Scenario 2
12.3.3. Scenario 3
12.3.4. Scenario 4
12.4. Concluding Remarks

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Lipid Contract Manufacturing Market, 2021-2030
13.4. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Type of Lipid
13.5. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Company Size
13.6. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Scale of Operation
13.7. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Region
13.7.1. Lipid Contract Manufacturing Market in North America, 2021-2030
13.7.2. Lipid Contract Manufacturing Market in Europe, 2021-2030
13.7.3. Lipid Contract Manufacturing Market in Asia-Pacific, 2021-2030
13.7.4. Lipid Contract Manufacturing Market in MENA, 2021-2030
13.7.5. Lipid Contract Manufacturing Market in Latin America, 2021-2030
13.7.6. Lipid Contract Manufacturing Market in Rest of the World, 2021-2030
14. CASE STUDY: APPLICATIONS OF LIPIDS AND LIPID FORMULATION TECHNOLOGIES
14.1. Chapter Overview
14.2. Biopharmaceutical Drug Classification System
14.3. Lipid-based Formulations as Drug Delivery Systems
14.3.1. Role of Lipids in mRNA Vaccines
14.3.2. Recent Developments in Lipid Nanoparticles
14.4. Lipid-based Formulation Technology Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
15. CONCLUDING REMARKS
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Liposoma
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Asha Van Rooijen, Founder and CEO
16.3. Exelead
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Rahul Keswani, Associate Director, Formulation Development
16.4. BioVectra
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Clement Mugabe, Acting Manager, Biotech Process Development and John Riley, Director, Process Development – Chemistry
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS